Astrazeneca Plc Adr Stock Current Valuation
| AZN Stock | USD 70.13 1.58 2.30% |
Valuation analysis of AstraZeneca PLC ADR helps investors to measure AstraZeneca PLC's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 23rd of April 2024, Enterprise Value is likely to grow to about 220.4 B, while Enterprise Value Over EBITDA is likely to drop 9.84. Fundamental drivers impacting AstraZeneca PLC's valuation include:
Price Book 5.4598 | Enterprise Value 132.5 B | Enterprise Value Ebitda 17.7384 | Price Sales 4.6651 | Forward PE 16.3132 |
Fairly Valued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC ADR is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for AstraZeneca PLC ADR is useful when determining the fair value of the AstraZeneca stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of AstraZeneca PLC. Since AstraZeneca PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AstraZeneca Stock. However, AstraZeneca PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 70.13 | Real 69.91 | Target 83.71 | Hype 70.13 |
The real value of AstraZeneca Stock, also known as its intrinsic value, is the underlying worth of AstraZeneca PLC ADR Company, which is reflected in its stock price. It is based on AstraZeneca PLC's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AstraZeneca PLC ADR helps investors to forecast how AstraZeneca stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: AstraZeneca PLC ADR Company Current Valuation Analysis
AstraZeneca PLC's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AstraZeneca PLC Current Valuation | 132.52 B |
Most of AstraZeneca PLC's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AstraZeneca Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for AstraZeneca PLC is extremely important. It helps to project a fair market value of AstraZeneca Stock properly, considering its historical fundamentals such as Current Valuation. Since AstraZeneca PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AstraZeneca PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AstraZeneca PLC's interrelated accounts and indicators.
Click cells to compare fundamentals
AstraZeneca Current Valuation Historical Pattern
Today, most investors in AstraZeneca PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AstraZeneca PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AstraZeneca PLC current valuation as a starting point in their analysis.
AstraZeneca PLC Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AstraZeneca PLC ADR has a Current Valuation of 132.52 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.
AstraZeneca Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in current valuation category among related companies.
AstraZeneca Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.066 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 132.52 B | ||||
| Shares Outstanding | 3.1 B | ||||
| Shares Owned By Institutions | 16.82 % | ||||
| Number Of Shares Shorted | 7.66 M | ||||
| Price To Earning | 103.39 X | ||||
| Price To Book | 5.46 X | ||||
| Price To Sales | 4.67 X | ||||
| Revenue | 45.81 B | ||||
| Gross Profit | 35.73 B | ||||
| EBITDA | 13.91 B | ||||
| Net Income | 6.9 B | ||||
| Cash And Equivalents | 4.52 B | ||||
| Cash Per Share | 1.46 X | ||||
| Total Debt | 28.62 B | ||||
| Debt To Equity | 0.89 % | ||||
| Current Ratio | 0.81 X | ||||
| Book Value Per Share | 25.25 X | ||||
| Cash Flow From Operations | 10.35 B | ||||
| Short Ratio | 1.61 X | ||||
| Earnings Per Share | 1.91 X | ||||
| Price To Earnings To Growth | 0.89 X | ||||
| Target Price | 81.81 | ||||
| Number Of Employees | 89.9 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 217.43 B | ||||
| Total Asset | 101.12 B | ||||
| Retained Earnings | 1.5 B | ||||
| Working Capital | (5.49 B) | ||||
| Current Asset | 16.01 B | ||||
| Current Liabilities | 14.87 B | ||||
| Annual Yield | 0.02 % | ||||
| Five Year Return | 2.99 % | ||||
| Net Asset | 101.12 B | ||||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
| 0.69 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
Moving against AstraZeneca Stock
| 0.76 | DNA | Ginkgo Bioworks Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.41 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out AstraZeneca PLC Piotroski F Score and AstraZeneca PLC Altman Z Score analysis. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.059 | Dividend Share 2.9 | Earnings Share 1.91 | Revenue Per Share 2.4547 | Quarterly Revenue Growth 0.073 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.